Index Rebal/Special Situations, Quiddity Advisors

Janaghan Jeyakumar, CFA

Index Rebal/Special Situations

Quiddity Advisors

Pan-Asia Catalysts/Events

Index Rebalance

<ul>
<li>CSI Medical Service represents the top 50 largest and most-liquid stocks involved in medical devices, medical care, medical informatization, and other medical themes from the Shanghai, Shenzhen, and Beijing Exchanges.</li>
<li>We expect three ADDs/DELs for the CSI Medical Service index and one-way flows of approximately US$213mn in the June 2026 index rebal event.</li>
<li>The reference period is about to end soon but there are some names that are still close to the border, according to our latest estimates.</li>
</ul>


CSI Medical Service represents the top 50 largest and most-liquid stocks involved in medical devices, medical care, medical informatization, and other medical themes from the Shanghai, Shenzhen, and Beijing Exchanges.
We expect three ADDs/DELs for the CSI Medical Service index and one-way flows of approximately US$213mn in the June 2026 index rebal event.
The reference period is about to end soon but there are some names that are still close to the border, according to our latest estimates.


Quiddity Leaderboard CSI Medical Jun26: Some Names Still Close to the Border

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Thematic (Sector/Industry)

<ul>
<li>APIs, generic drugs, CXO, low-end medical consumables will be hit the most due to tariffs.Investors are advised to be cautious on these subsectors as companies’ performance would be negatively affected. </li>
<li>As the tariff war is heating up, blood products, innovative medical device, innovative drugs, chain pharmacies, innovative medical services, pharmaceutical distribution business could be "safe haven assets" for investors. </li>
<li>The logic behind tariffs is to attack China's effective supply and trigger China's overcapacity problem, thereby weakening effective demand and reducing capital accumulation rate, so as to attack the RMB.</li>
</ul>


APIs, generic drugs, CXO, low-end medical consumables will be hit the most due to tariffs.Investors are advised to be cautious on these subsectors as companies’ performance would be negatively affected. 
As the tariff war is heating up, blood products, innovative medical device, innovative drugs, chain pharmacies, innovative medical services, pharmaceutical distribution business could be "safe haven assets" for investors. 
The logic behind tariffs is to attack China's effective supply and trigger China's overcapacity problem, thereby weakening effective demand and reducing capital accumulation rate, so as to attack the RMB.


The Impact of Trump's Tariffs on China Healthcare - The Victims, And the Safe Haven Assets

Guangzhou Wondfo Biotech C-A / Index Rebalance

<ul>
<li>CSI Medical Service represents the top 50 largest and most-liquid stocks involved in medical devices, medical care, medical informatization, and other medical theme from the Shanghai, Shenzhen and Beijing Exchanges.</li>
<li>In this insight, we have presented our final expectations for ADDs and DELs for the upcoming semiannual index rebal event in June 2026.</li>
<li>We expect three ADDs and three DELs for the CSI Medical Service index during this index review event.</li>
</ul>


CSI Medical Service represents the top 50 largest and most-liquid stocks involved in medical devices, medical care, medical informatization, and other medical theme from the Shanghai, Shenzhen and Beijing Exchanges.
In this insight, we have presented our final expectations for ADDs and DELs for the upcoming semiannual index rebal event in June 2026.
We expect three ADDs and three DELs for the CSI Medical Service index during this index review event.


Quiddity Leaderboard CSI Medical Jun26: Final Expectations

HK/China Equity Long-Short

Osbert Tang, CFA

Equity Capital Markets

Cofoe Medical Technology / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/cofoe-medical-technology-co-ltd" target="_blank" data-smartkarma-citation="entities:45716:1" rel="noopener">Cofoe Medical Technology (1187 HK)</a> launched its H-share IPO at HK$39.33, valuing the stock at 16.4x PER for FY26, a discount to the global peers.</li>
<li>Its 3-year EPS CAGR of 18.8% is ahead of the global average, but its market capitalisation of HK$9.3bn is materially smaller.</li>
<li>Using a 10% PER discount to global peers, it has a fair range of HK$41.8-45.2, which equals a reasonable 27-33% discount to its A-share <a href="https://www.smartkarma.com/entities/cofoe-medical-technology-co-lt" target="_blank" data-smartkarma-citation="entities:34791:1" rel="noopener">Cofoe Medical (301087 CH)</a>. </li>
</ul>



Cofoe Medical Technology (1187 HK) launched its H-share IPO at HK$39.33, valuing the stock at 16.4x PER for FY26, a discount to the global peers.
Its 3-year EPS CAGR of 18.8% is ahead of the global average, but its market capitalisation of HK$9.3bn is materially smaller.
Using a 10% PER discount to global peers, it has a fair range of HK$41.8-45.2, which equals a reasonable 27-33% discount to its A-share Cofoe Medical (301087 CH). 


Cofoe Medical Technology (1187 HK) IPO: Priced with Reasonable Potential Gain

<ul>
<li>CSI Medical Service represents the top 50 largest and most-liquid stocks involved in medical devices, medical care, medical informatization, and other medical themes from the Shanghai, Shenzhen, and Beijing Exchanges.</li>
<li>In this insight, we have presented our expectations for ADDs and DELs for the upcoming semiannual index rebal event in June 2026.</li>
<li>We expect three ADDs/DELs for the CSI Medical Service index during this index review event based on the latest available data.</li>
</ul>


CSI Medical Service represents the top 50 largest and most-liquid stocks involved in medical devices, medical care, medical informatization, and other medical themes from the Shanghai, Shenzhen, and Beijing Exchanges.
In this insight, we have presented our expectations for ADDs and DELs for the upcoming semiannual index rebal event in June 2026.
We expect three ADDs/DELs for the CSI Medical Service index during this index review event based on the latest available data.


Quiddity Leaderboard CSI Medical Jun26: 3 ADDs/DELs Expected For Now But It Could Become 4

China

Zhende Medical Co., Ltd. manufactures medical products. The Company researches, develops, produces, and sells medical dressings, pressure treatment and fixation, modern wound care, surgical infection management, and other products. Zhende Medical markets its products worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Zhende Medical Co Ltd (603301 CH)

Quiddity Leaderboard CSI Medical Jun26: Some Names Still Close to the Border

Our current estimate of impacts for the expected index changes range from 0.6x ADV to 3.5x ADV. Individual flow sizes range from US$11mn to US$85mn

Janaghan Jeyakumar, CFA

The Impact of Trump's Tariffs on China Healthcare - The Victims, And the Safe Haven Assets

As tariff war is heating up, some sectors in China healthcare will be victims, but there will also safe haven assets.The logic behind tariffs is to...

Xinyao (Criss) Wang

Quiddity Leaderboard CSI Medical Jun26: Final Expectations

We estimate the CSI Medical June 2026 index rebalance to trigger one-way flow of ~US$319mn. The results could be announced on 29th May 2026.

Janaghan Jeyakumar, CFA

Cofoe Medical Technology (1187 HK) IPO: Priced with Reasonable Potential Gain

Cofoe Medical Technology's H-share IPO values the stock at a discount to global peers. We estimate a fair range of HK$41.8-45.2, balancing the...

Osbert Tang, CFA

Quiddity Leaderboard CSI Medical Jun26: 3 ADDs/DELs Expected For Now But It Could Become 4

One potential ADD and one potential DEL are still close to the border and those names could trigger an extra index change depending on relative...

Janaghan Jeyakumar, CFA

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Quiddity Leaderboard CSI Medical Jun26: Some Names Still Close to the Border

Our current estimate of impacts for the expected index changes range from 0.6x ADV to 3.5x ADV. Individual flow sizes range from US$11mn to US$85mn

Janaghan Jeyakumar, CFA

The Impact of Trump's Tariffs on China Healthcare - The Victims, And the Safe Haven Assets

As tariff war is heating up, some sectors in China healthcare will be victims, but there will also safe haven assets.The logic behind tariffs is to...

Xinyao (Criss) Wang

Quiddity Leaderboard CSI Medical Jun26: Final Expectations

We estimate the CSI Medical June 2026 index rebalance to trigger one-way flow of ~US$319mn. The results could be announced on 29th May 2026.

Janaghan Jeyakumar, CFA

Cofoe Medical Technology (1187 HK) IPO: Priced with Reasonable Potential Gain

​Cofoe Medical Technology's H-share IPO values the stock at a discount to global peers. We estimate a fair range of HK$41.8-45.2, balancing the...

Osbert Tang, CFA

Quiddity Leaderboard CSI Medical Jun26: 3 ADDs/DELs Expected For Now But It Could Become 4

One potential ADD and one potential DEL are still close to the border and those names could trigger an extra index change depending on relative...

Janaghan Jeyakumar, CFA

Cofoe Medical Technology's H-share IPO values the stock at a discount to global peers. We estimate a fair range of HK$41.8-45.2, balancing the...